Proteomics International Laboratories Ltd
Company Profile
Business description
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.
Contact
6 Verdun Street
QEII Medical Centre, QQ Block
Nedlands
PerthWA6009
AUST: +61 893891992
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Proteomics International Laboratories Ltd News & Analysis
video
Proteomics set for growth, says Kardinia
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,680.50 | 27.80 | 0.32% |
| CAC 40 | 7,824.80 | 53.85 | 0.69% |
| DAX 40 | 21,274.25 | 232.25 | 1.10% |
| Dow JONES (US) | 44,025.81 | 537.98 | 1.24% |
| FTSE 100 | 8,569.98 | 21.69 | 0.25% |
| HKSE | 19,778.77 | 327.78 | -1.63% |
| NASDAQ | 19,756.78 | 126.58 | 0.64% |
| Nikkei 225 | 39,646.25 | 618.27 | 1.58% |
| NZX 50 Index | 13,037.14 | 15.76 | -0.12% |
| S&P 500 | 6,049.24 | 52.58 | 0.88% |
| S&P/ASX 200 | 8,429.80 | 27.40 | 0.33% |
| SSE Composite Index | 3,213.62 | 29.00 | -0.89% |